BIA 10-2474 is primarily investigated for its potential application in the treatment of neurological disorders. It functions as a fatty acid amide hydrolase (FAAH) inhibitor, which means it can increase the levels of endocannabinoids in the brain. This mechanism is being explored for its potential to alleviate symptoms of conditions such as anxiety, chronic pain, and neurodegenerative diseases. By modulating the endocannabinoid system, BIA 10-2474 could offer therapeutic benefits in managing these disorders, although its development has faced challenges due to safety concerns observed in clinical trials. Research continues to better understand its efficacy and safety profile for future medical applications.